Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Shares of BioCryst Pharmaceuticals Jumped Higher Today

By Brian Orelli, PhD – Updated May 11, 2020 at 2:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are still hot on the idea that its antiviral drug galidesivir could be used for COVID-19.

What happened

Shares of BioCryst Pharmaceuticals (BCRX 3.22%) are up 13% at 2:09 p.m., continuing a two-day run that's seen its shares increase 36% since the close on Thursday. It appears investors are excited about the prospects for its antiviral galidesivir as a treatment for COVID-19, the disease caused by the novel coronavirus.

So what

BioCryst has started testing galidesivir in a placebo-controlled study in Brazil that will evaluate three different doses of the drug in a total of 24 patients with moderate to severe COVID-19. Once the best dose is found, up to 42 patients will be enrolled in the expanded group.

Patient and doctors behind a sign that reads, "Caution, outbreak alert"

Image source: Getty Images.

BioCryst is more than just a play on COVID-19. The company has developed berotralstat for patients with hereditary angioedema (HAE), an inherited disease characterized by episodes of severe swelling. The drug is under review by the Food and Drug Administration, the Pharmaceuticals and Medical Devices Agency in Japan, and the European Medicines Agency.

Investors may be jumping in ahead of potential approvals in Japan (sometime in the second half of this year), the U.S. (likely on or before Dec. 3, 2020), and the EU (likely in the first half of next year). Although with multiple drugs available to treat HAE, BioCryst's sales force will have its work cut out for it.

Now what

At a market cap of $820 million, BioCryst Pharmaceuticals isn't particularly expensive; a few hundred million in sales of berotralstat would justify the valuation.

But investors should keep an eye on the company's cash runway. With a nest egg of just $114.6 million at the end of the first quarter and a plan to spend at least $100 million more this year, BioCryst will need to raise additional capital through a secondary offering, licensing one of its pipeline drugs, or perhaps a royalty financing for berotralstat before the biotech can grow into its current valuation.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$12.50 (3.22%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.